• Filana Therapeutics disclosed April 15, 2026 publication in Epilepsia of preclinical results for simufilam in a severe mouse model of TSC-related epilepsy.
• Study results were previously presented as top-line findings in August 2025.
• Data showed simufilam slowed worsening of seizure activity versus vehicle, supporting continued development in TSC-related epilepsy.
• Company is working to resolve an FDA clinical hold disclosed in December 2025, with a program update expected in coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150800PRIMZONEFULLFEED9690158) on April 15, 2026, and is solely responsible for the information contained therein.